Hyalose, LLC is a biotechnology company focused on the commercialization of unique recombinant technologies for producing Hyaluronic Acid (HA), an important biomolecule for many healthcare and cosmetic applications.
Oklahoma Medical Research Foundation has developed a highly effective and safe therapeutic for the treatment of glioblastoma. The compound, OKN-007, has the unique ability to cross the blood-brain barrier and has been successfully shown to decrease both tumor size and tumor vasculature in animal models of glioblastoma.
Moleculera Labs provides personalized clinical testing services for individuals suspected of suffering from PANDAS/PANS, which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders (OCD) and sometimes Autism Spectrum Disorders.
DormaTarg is a pharmaceutical company developing a series of small molecule oncology therapeutics that inhibit recurrence in metastasis prone cancers, with an initial focus on Triple Negative Breast Cancer.
Otologic Pharmaceutics, Inc. (OP) is an Oklahoma-headquartered organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balanced health.
Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.?
Charlesson, an Oklahoma-based pharmaceutical company, is actively engaged in the development of therapeutics for treating debilitating ophthalmic diseases. Their product pipeline includes pharmaceutical treatments for Age-Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammation, Angiogenesis, and systemic diabetes.
Drik is a pre clinical toxicology services laboratory for drug safety evaluation. They do preclinical screening tests for cosmetic industry and non clinical toxicology testing for chemical manufacturing.